Once-Weekly Insulin Icodec: What You Need to Know About This Long-Acting Option

Insulin icodec is engineered differently from traditional insulins to stay in your body much longer. The insulin molecule binds reversibly to albumin, a protein in your blood, which slows its release and keeps glucose-lowering effects steady throughout the week. This design allows it to work for approximately 7 days after a single injection.

The longer action means fewer injections—once weekly instead of daily—which may simplify insulin management for some people with diabetes.

Research shows that icodec delivers consistent results week to week. The variation in insulin exposure from one person to another is very low (5.9% intra-individual coefficient of variation), meaning the insulin performs reliably regardless of when you inject it or where on your body you inject.

Icodec causes dose-proportional glucose lowering, which means doubling your dose roughly doubles the effect. This predictability can make it easier to adjust your insulin regimen with your healthcare provider.

When you first start icodec, your body reaches a steady state—the point where the insulin level stabilizes—after 3 to 4 weeks. If your healthcare provider gives you a 50% higher first dose, this timeline can be shortened by one week.

This gradual buildup is important to understand: your insulin levels won't reach full effect immediately, so close monitoring during the first month is necessary.

Studies examined how icodec performs during physical activity and prolonged fasting—situations where blood sugar can drop unpredictably. Glucose levels remained within recommended targets, and no clinically significant or severe low blood sugar events occurred without supplemental glucose.

When additional carbohydrates were needed, they effectively prevented low blood sugar. This suggests icodec may be manageable during these common daily situations, though individual responses vary.

If an accidentally higher dose is given, the risk of low blood sugar with icodec is comparable to daily basal insulins. Your body's natural counter-regulation—the hormones and systems that raise blood sugar during a low—works robustly with icodec.

This means the safeguards against severe hypoglycemia are similar to insulins already in use, which is reassuring for people considering this option.

Research included people with both Type 1 and Type 2 diabetes across different ages, sexes, races, and ethnicities. Icodec's performance did not change meaningfully based on age, sex, kidney or liver function, or blood albumin levels, suggesting it may work consistently across diverse populations.

This is still early-stage research. Icodec is not yet approved for routine use, and more clinical studies are underway to confirm safety and effectiveness in real-world settings.

Source: Clinical pharmacokinetics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.